Keyphrases
Rheumatoid Arthritis
100%
Pharmacogenetics
39%
Disease-modifying Antirheumatic Drugs (DMARDs)
24%
Methotrexate
22%
Pharmacogenomics
16%
Systemic Lupus Erythematosus
10%
National Cohort
10%
Status Report
10%
Patient Response
8%
Tumor Necrosis Factor Antagonist
7%
Rheumatic Diseases
7%
Single nucleotide Polymorphism
7%
Clinical Trials
7%
Joint Damage
7%
Tumor Necrosis Factor-α
7%
Lupus Nephritis
6%
Methotrexate Toxicity
6%
Rheumatic Disorders
6%
Polymorphism
6%
Drug Therapy
6%
Tumour Necrosis Factor Inhibitor (TNFi)
6%
Scleroderma
6%
Risk Factors
5%
Osteoporosis
5%
Rheumatoid Arthritis Treatment
5%
Biological Agents
5%
Infliximab
5%
Vitamin D Deficiency
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
80%
Inflammatory Arthritis
80%
Pharmacogenetics
38%
Disease Modifying Antirheumatic Drug
19%
Methotrexate
16%
Tumor Necrosis Factor
15%
Diseases
15%
Pharmacogenomics
12%
Biological Product
11%
Rheumatic Disease
7%
Systemic Lupus Erythematosus
7%
Clinical Trial
7%
Pharmacotherapy
5%
Placebo
5%
Infection
5%
Medicine and Dentistry
Rheumatoid Arthritis
28%
Inflammatory Arthritis
28%
Vasculitis
7%
Rheumatic Disorder
6%
Lupus Nephritis
6%
Diseases
6%
Systemic Lupus Erythematosus
5%
Scleroderma
5%
Pharmacogenetics
5%